Castle Biosciences to Showcase Innovations at Investor Conferences

Castle Biosciences, Inc. (Nasdaq: CSTL), known for its groundbreaking approaches in healthcare diagnostics, is gearing up to participate in several investor conferences that highlight its advancements in guiding patient care. The company is committed to improving health outcomes through innovative tests, and these upcoming events provide a platform to showcase its contributions to the medical field.

Upcoming Presentations

On September 15, 2026, at 10:50 AM Eastern Time, Castle Biosciences' executive management will present a comprehensive overview of the company at Baird's 2026 Global Healthcare Conference. Attendees can tune in via a live audio webcast available on Castle Biosciences’ investor relations webpage. Following the live presentation, a replay will be accessible, allowing more stakeholders to engage with the company’s latest developments.

In addition to the Baird conference, Castle will also engage in one-on-one meetings during the 10th Annual Lake Street Best Ideas Growth (BIG10) Conference on September 10, 2026. These meetings are a significant opportunity for investors to gain deeper insights into the company's operations and future directions. Requests for meetings can be made exclusively through Lake Street Capital Markets.

About Castle Biosciences

Castle Biosciences focuses on enhancing patient care through personalized and clinically actionable solutions. Their diagnostic tests primarily cater to dermatologic and gastroenterological diseases, allowing healthcare providers to make informed decisions about patient management. The company is driven by a strong ethos that prioritizes putting patients first and empowering clinicians with information through advanced molecular testing.

Innovative Products and Solutions

The firm’s suite of products includes notable tests such as DecisionDx-Melanoma, TissueCypher, and DecisionDx-UMSeq. Each of these innovations aims to provide clearer insights into disease management, thereby improving treatment approaches. By leveraging rigorous science and state-of-the-art technology, Castle Biosciences supports healthcare professionals in creating tailored treatment plans that enhance patient outcomes.

A significant part of Castle's mission is to ensure that both patients and clinicians are equipped with the tools they need for effective disease management. By maintaining a focus on rigorous scientific processes, the company is positioned at the forefront of diagnostic solutions that facilitate informed treatment decisions.

Castle Biosciences continues to engage with its audience through various platforms, including LinkedIn, Instagram, Facebook, and X, reflecting its commitment to being accessible and transparent in its operations.

Conclusion

With its active participation in upcoming investor conferences, Castle Biosciences is not only reinforcing its mission to improve healthcare through innovative testing but is also fostering stronger relationships with investors. As the company unveils its advancements in diagnostics, stakeholders can expect insightful discussions around future growth and the transformative impact of Castle's products on patient wellbeing.

For more information, you can visit the official website of Castle Biosciences at CastleBiosciences.com. Additionally, media inquiries can be directed to Allison Marshall at the company.